Rates of new indication for antithrombotic drugs in people with cognitive impairment: implications for anti-amyloid monoclonal antibody treatment
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objectives
Antithrombotic drugs—anticoagulants and thrombolytics— may interact with anti-amyloid monoclonal antibodies (mAbs) to increase intracranial hemorrhage risk, so expert guidance recommends against their co-prescription. We aimed to estimate how many people with mild cognitive impairment (MCI) or dementia develop a new cardiovascular indication for antithrombotic drugs.
Methods
In a longitudinal cohort of adults ≥65 years old from the Health and Retirement Study (2010-2020) with linked Medicare claims and no prior indication for anticoagulants, cognition was categorized as normal, MCI, or dementia. We fit Fine-Gray separate survival models accounting for competing risk of death to estimate 1-year incidence of atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE), acute myocardial infarction (MI), and stroke.
Results
Among 12,373 participants (mean age 73 years, 59% female), for MCI, 1-year incidence was 1.7% for AF, 1.2% for DVT, 0.4% for PE, 1.2% for AMI, 2.0% for stroke, and 5.7% for any indication. In dementia, 1-year rates were 1.7% for AF, 1.8% for DVT, 0.3% for PE, 1.0% for AMI, 2.4% for stroke, and 6.7% for any indication.
Discussion
Our finding inform shared decision-making about the tradeoffs of anti-amyloid mAbs.
